BURLINGAME, Calif.--(BUSINESS WIRE)--Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvants, adjuvanted vaccines and immunotherapeutics for infectious diseases and cancer, today announced it has entered into an exclusive license agreement with Colby Pharmaceutical Company for the worldwide development and commercialization of Juvaris’ Cationic Lipid-DNA Complex (CLDC) technology and JVRS-100 product candidate, including its intellectual property estate and human clinical development programs, in the field of human (non-animal) health.
